Ost-müük Sonnet BioTherapeutics Holdings, Inc. - SONN CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | - | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | N/A |
Avatud* | N/A |
Aastane muutus* | N/A |
Päeva ulatus* | N/A |
52 nädala ulatus | 0.55-6.68 |
Keskmine maht (10 päeva) | 132.66K |
Keskmine maht (3 kuud) | 9.60M |
Turukapitalisatsioon | 12.23M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 20.23M |
Tulu | 257.40K |
EPS | -6.20 |
Dividendid (% kasumist) | N/A |
Beeta | 0.69 |
Järgmine tuluaruande kuupäev | May 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|
Sonnet BioTherapeutics Holdings, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kogutulu | 0.48363 | 0 | 30.1431 | 30.7335 | 41.4329 |
Tulu | 0.48363 | 30.1431 | 30.7335 | 41.4329 | |
Kulud, Kokku | 28.2449 | 28.1255 | 37.125 | ||
Brutokasum | 1.89824 | 2.60793 | 4.30781 | ||
Kogu tegevuskulu | 25.5711 | 24.2378 | 46.2213 | 36.1028 | 46.7635 |
Müük/Üldine/admin kulud, kokku | 8.93651 | 7.53372 | 6.98426 | 4.26062 | 4.86478 |
Depreciation / Amortization | 1.84235 | 1.81683 | 2.2828 | ||
Ootamatud kulutused (tulu) | 0 | 6.8265 | 9.14985 | 1.89982 | 2.49093 |
Tulud majandustegevusest | -25.0874 | -24.2378 | -16.0782 | -5.36933 | -5.33069 |
Intressitulud (kulu), muud tulud, neto | -0.02202 | -0.02734 | -0.67357 | -2.54944 | -2.59296 |
Muud, neto | 0.1255 | -0.61784 | -0.15278 | 0.11298 | |
Netotulu enne makse | -24.984 | -24.2651 | -17.3696 | -8.07155 | -7.81066 |
Netotulu pärast makse | -24.984 | -24.2651 | -17.4434 | -7.37032 | -2.32954 |
Vähemuse intress | 0.40239 | 0.50796 | 0.37146 | ||
Netotulu enne erikulusid | -24.984 | -24.2651 | -17.041 | -6.86237 | -1.95807 |
Erakorralised kulud kokku | -0.68541 | 0.00795 | -4.8367 | ||
Netotulu | -24.984 | -24.2651 | -17.7264 | -6.85442 | -6.79477 |
Arvestatav tulu, v a erikulud | -24.984 | -65.604 | -17.1532 | -6.98097 | -2.06628 |
Arvestatav tulu, koos erikuludega | -24.984 | -65.604 | -17.8386 | -6.97302 | -6.90298 |
Jaotuse korrigeerimine | |||||
Jaotamisele kuuluv netotulu | -24.984 | -65.604 | -17.8386 | -6.97302 | -6.90298 |
Keskmine jaotamisele kuuluv aktsia kohta | 24.5473 | 9.42048 | 0.26842 | 0.13538 | 0.09711 |
Jaotatav EPS, v a erakorralised kulud | -1.01779 | -6.96398 | -63.9051 | -51.5642 | -21.2771 |
Jaotamisele kuuluv normaal-EPS | -1.01779 | -6.23933 | -41.7477 | -42.4429 | -4.60472 |
Total Adjustments to Net Income | 0 | -41.3389 | -0.11224 | -0.1186 | -0.10821 |
Uuringud ja arendus | 16.6346 | 9.87756 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kogutulu | 0.09532 | 0.1298 | 0.48363 | 0 | 0 |
Kogu tegevuskulu | 8.30554 | 6.34475 | 7.43051 | 6.23953 | 6.03703 |
Müük/Üldine/admin kulud, kokku | 1.90026 | 2.07889 | 2.39479 | 2.35227 | 2.19663 |
Uuringud ja arendus | 6.40527 | 4.26587 | 5.03572 | 3.88726 | 3.8404 |
Tulud majandustegevusest | -8.21022 | -6.21495 | -6.94688 | -6.23953 | -6.03703 |
Intressitulud (kulu), muud tulud, neto | 0.00172 | 0.01397 | -0.00518 | -0.00151 | -0.00208 |
Netotulu enne makse | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Netotulu pärast makse | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Netotulu enne erikulusid | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Netotulu | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Arvestatav tulu, v a erikulud | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Arvestatav tulu, koos erikuludega | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Jaotamisele kuuluv netotulu | -8.2085 | -6.20098 | -6.95207 | -6.11554 | -6.03911 |
Keskmine jaotamisele kuuluv aktsia kohta | 60.2948 | 60.293 | 39.7423 | 22.5022 | 18.7429 |
Jaotatav EPS, v a erakorralised kulud | -0.13614 | -0.10285 | -0.17493 | -0.27178 | -0.32221 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.13614 | -0.10285 | -0.17493 | -0.27178 | -0.32221 |
Muud, neto | 0 | 0.1255 | |||
Tulu | 0.09532 | 0.1298 | 0.48363 | ||
Ootamatud kulutused (tulu) | 0 | ||||
Total Adjustments to Net Income | 0 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 28.8115 | 7.63764 | 1.16959 | 1.34389 | 1.79956 |
Raha ja lühiajalised investeeringud | 27.6221 | 7.3499 | 0.50068 | 0.52378 | 0.27298 |
Cash | 27.6221 | 7.3499 | 0.50068 | 0.52378 | 0.27298 |
Laekumata arved, neto | 0.13189 | 0.32536 | 0.47599 | ||
Accounts Receivable - Trade, Net | 0.13189 | 0.32536 | 0.47599 | ||
Total Inventory | 0.28711 | 0.33521 | 0.46076 | ||
Prepaid Expenses | 1.18947 | 0.28774 | 0.24958 | 0.15921 | 0.32432 |
Other Current Assets, Total | 0.00034 | 0.00034 | 0.26552 | ||
Total Assets | 28.9938 | 7.99441 | 31.5329 | 29.7932 | 30.183 |
Property/Plant/Equipment, Total - Net | 0.18227 | 0.27381 | 17.2985 | 9.75627 | 8.54859 |
Goodwill, Net | 8.56789 | 10.5644 | 12.6478 | ||
Intangibles, Net | 3.657 | 4.46982 | 5.89673 | ||
Long Term Investments | 0.69086 | 1.18608 | 1.29033 | ||
Total Current Liabilities | 6.70335 | 4.72448 | 18.0955 | 13.0251 | 14.906 |
Payable/Accrued | 4.23064 | 6.17614 | 5.97225 | ||
Notes Payable/Short Term Debt | 0.00075 | 0.02118 | 0 | 3 | 3 |
Current Port. of LT Debt/Capital Leases | 6.63096 | 3.66319 | 5.74191 | ||
Other Current Liabilities, Total | 0.51637 | 0.5 | -0.00191 | 0.18573 | 0.19185 |
Total Liabilities | 6.73396 | 4.97449 | 35.1406 | 22.3627 | 19.4766 |
Total Long Term Debt | 0 | 0.12488 | 0.7097 | 3.67491 | 0.85239 |
Long Term Debt | 0 | 0.12488 | 0.7097 | 3.67491 | 0.85239 |
Deferred Income Tax | 0.1023 | 0.07677 | 0.77936 | ||
Minority Interest | 0.45578 | 0.82704 | 0.78245 | ||
Other Liabilities, Total | 0.03061 | 0.12513 | 15.7774 | 4.75898 | 2.15638 |
Total Equity | 22.2598 | 3.01992 | -3.60779 | 7.43049 | 10.7064 |
Common Stock | 0.00603 | 0.00147 | 0.00104 | 0.00037 | 0.00031 |
Additional Paid-In Capital | 83.943 | 39.7237 | 71.506 | 64.7569 | 60.7503 |
Retained Earnings (Accumulated Deficit) | -61.6892 | -36.7053 | -75.0684 | -57.1247 | -49.1093 |
Other Equity, Total | -0.04644 | -0.20212 | -0.9349 | ||
Total Liabilities & Shareholders’ Equity | 28.9938 | 7.99441 | 31.5329 | 29.7932 | 30.183 |
Total Common Shares Outstanding | 60.2506 | 14.7241 | 0.40017 | 0.1429 | 0.11715 |
Other Long Term Assets, Total | 0 | 0.08296 | 0.149 | 2.47283 | |
Accrued Expenses | 2.40493 | 2.14574 | 7.23577 | 0 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Property/Plant/Equipment, Total - Gross | 22.8597 | ||||
Accumulated Depreciation, Total | -5.56115 | ||||
Accounts Payable | 3.7813 | 2.05756 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 14.9157 | 20.5837 | 28.8115 | 6.9724 | 7.39801 |
Raha ja lühiajalised investeeringud | 13.6355 | 19.4097 | 27.6221 | 6.03819 | 6.73881 |
Cash | 13.6355 | 19.4097 | 27.6221 | 6.03819 | 6.73881 |
Prepaid Expenses | 1.28013 | 1.17403 | 1.18947 | 0.93421 | 0.6592 |
Total Assets | 15.0463 | 20.7406 | 28.9938 | 7.17583 | 7.62551 |
Property/Plant/Equipment, Total - Net | 0.13063 | 0.15682 | 0.18227 | 0.20343 | 0.2275 |
Other Long Term Assets, Total | 0 | 0 | 0 | ||
Total Current Liabilities | 6.51296 | 4.34463 | 6.70335 | 5.75173 | 5.3981 |
Accounts Payable | 4.03642 | 2.11229 | 3.7813 | 2.15079 | 1.91353 |
Accrued Expenses | 2.18454 | 1.84502 | 2.40493 | 2.6002 | 2.98382 |
Notes Payable/Short Term Debt | 0.00075 | 0.00075 | 0.00075 | 0.00075 | 0.00075 |
Other Current Liabilities, Total | 0.29126 | 0.38658 | 0.51637 | 1 | 0.5 |
Total Liabilities | 6.51296 | 4.34963 | 6.73396 | 5.8072 | 5.6032 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0.1255 |
Long Term Debt | 0 | 0 | 0.1255 | ||
Other Liabilities, Total | 0 | 0.005 | 0.03061 | 0.05546 | 0.0796 |
Total Equity | 8.53333 | 16.3909 | 22.2598 | 1.36864 | 2.02231 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00603 | 0.00603 | 0.00603 | 0.00248 | 0.00212 |
Additional Paid-In Capital | 84.626 | 84.2751 | 83.943 | 56.1033 | 50.6418 |
Retained Earnings (Accumulated Deficit) | -76.0987 | -67.8902 | -61.6892 | -54.7371 | -48.6216 |
Total Liabilities & Shareholders’ Equity | 15.0463 | 20.7406 | 28.9938 | 7.17583 | 7.62551 |
Total Common Shares Outstanding | 60.2631 | 60.2506 | 60.2506 | 24.7579 | 21.1973 |
Total Preferred Shares Outstanding | 0 | 0 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -24.984 | -24.2651 | -18.465 | -7.19927 | -7.16624 |
Raha majandustegevusest | -22.5522 | -15.6148 | -4.04655 | -1.10963 | -0.72443 |
Raha majandustegevusest | 0.01246 | 0.00829 | 1.84235 | 1.81683 | 2.2828 |
Mittelikviidsed varad | 1.33325 | 7.24657 | 12.6501 | 2.42771 | 3.55978 |
Muutused tööjõus | 1.08601 | 1.39547 | -0.07394 | 1.8451 | 0.59922 |
Tulu investeeringutelt | -0.00362 | -0.07618 | 0.67867 | -2.05103 | -1.1643 |
Kapitalikulutused | -0.00362 | -0.07618 | -0.47288 | -1.69875 | -1.62546 |
Muud rahavood investeeringutelt, kokku | 1.15155 | -0.35228 | 0.46116 | ||
Rahavood investeeringutelt | 42.828 | 23.0052 | 3.3434 | 2.11544 | 2.08154 |
Rahavoogudesse investeerimine | 0 | -5.98381 | 3.19034 | 0.69884 | 0.43171 |
Aktsiate emiteerimine (tagasiost), neto | 42.8485 | 28.8603 | 0.15306 | 1.68718 | 1.28788 |
Laenu väljastamine (kustutamine), neto | -0.02044 | 0.12868 | 0 | -0.27058 | 0.36195 |
Muutused valuutakursside kõikumisest | 0.00139 | 0.00309 | -0.02288 | ||
Rahaline kogumuutus | 20.2722 | 7.31425 | -0.02309 | -1.04213 | 0.16992 |
Cash Taxes Paid | 0.11071 | 0.04059 | 0.02763 | ||
Makstud intressid | 0 | 0.55635 | 0.5539 | 0.83982 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -14.4095 | -6.20098 | -24.984 | -18.0319 | -11.9164 |
Cash From Operating Activities | -13.7009 | -8.09235 | -22.5522 | -16.6141 | -10.7693 |
Cash From Operating Activities | 0.00642 | 0.00321 | 0.01246 | 0.00925 | 0.00616 |
Non-Cash Items | 1.01381 | 0.47431 | 1.33325 | 0.99402 | 0.78088 |
Changes in Working Capital | -0.31166 | -2.36889 | 1.08601 | 0.41451 | 0.36002 |
Cash From Investing Activities | -0.28563 | -0.12 | -0.00362 | 0 | 0 |
Capital Expenditures | -0.28563 | -0.12 | -0.00362 | 0 | 0 |
Cash From Financing Activities | 0 | 0 | 42.828 | 15.3024 | 10.1582 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 42.8485 | 15.3228 | 10.1786 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -0.02044 | -0.02044 | -0.02044 |
Net Change in Cash | -13.9865 | -8.21235 | 20.2722 | -1.31171 | -0.61109 |
Financing Cash Flow Items | 0 | 0 |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sonnet BioTherapeutics Holdings, Inc. Company profile
Ettevõttest Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. on kliinilise faasi biofarmatseutiline ettevõte. Ettevõtte tehnoloogia, nimelt täielikult inimese albumiini sidumine (FHAB), aitab arendada bioloogilisi ravimeid. FHAB kasutab täielikult inimese üheahelalist antikeha fragmenti, mis on seotud kas ühe või kahe terapeutilise molekuliga, mis on võimelised mõjutama ühe- või kahespetsiifilisi toimemehhanisme. FHAB-konstruktsioon sisaldab domeeni, mis on kavandatud seonduma ja haakuma inimese seerumi albumiiniga, et seda saaks transportida sihtmärkidesse, näiteks tahketesse kasvajatesse või lümfisüsteemi. Konstruktsioon on loodud selleks, et parandada ravimi akumuleerumist spetsiifilistes kudedes ning pikendada toime kestust organismis. FHAB arenduskandidaate toodetakse imetajate rakukultuuris, mis võimaldab glükosüülimist, vähendades seeläbi immunogeensuse riski. FHAB-tehnoloogia võib aidata ravimite väljatöötamisel paljudes inimhaiguste valdkondades, sealhulgas onkoloogias, autoimmuunsetes, patogeensetes, põletikulistes ja hematoloogilistes seisundites.
Industry: | Pharmaceuticals (NEC) |
100 Overlook Center
Suite 102
08540
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com